IDX 184 - Merck (MSD)
Q3 2012 Results (Idenix) - Nov 2, 2012 - Anticipated interim results from P2b trial (IDX184+pegylated interferon+ribavirin combination) at AASLD, (Nov 13, 2012) 
Anticipated P2b data • Hepatitis C Virus
http://www.larvolonline.com/tlg/ccdb/IdenixQ32012ResultsNov012012.pdf
 
Nov 2, 2012
 
.